🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,931 results for “The” Clear

  1. Family Therapy based on Structural Family Therapy

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Use Disorders

    phase 2 other completed

    1 trial

  2. Famotidine

    United Therapeutics Europe Ltd

    2019 Novel Coronavirus Disease

    phase 2 small molecule terminated

    3 trials

  3. Fasedienol Nasal Spray - Placebo Nasal Spray

    Vistagen Therapeutics

    Social Anxiety Disorder

    phase 2 small molecule active

    1 trial

  4. Fentanyl

    United Therapeutics Europe Ltd

    Healthy

    phase 2 small molecule completed

    1 trial

  5. Fianlimab, LIBTAYO 350 mg concentrate for solution for infusion.

    CERO THERAPEUTICS HOLDINGS, INC.

    Pleural mesothelioma

    phase 2 small molecule active

    1 trial

  6. Fianlimab, LIBTAYO 350 mg concentrate for solution for infusion.

    Disc Medicine

    Metastatic solid tumors, these may include but are not limited to melanoma, non-small-cell lung carcinoma (NSCLC), cervical cancer, microsatellite instable (MSI)-high/deficient mismatch repair (dMMR) cancer, renal cell carcinoma (RCC), CSCC, urothelial cell carcer (UCC), small cell lung cancer (SCLC) and head and neck squamous cell carcinoma (HNSCC).

    phase 2 small molecule active

    1 trial

  7. Fibromun, Dacarbazine medac 1000 mg, powder for solution for infusion

    Philogen S.p.A.

    Unresectable and/or metastatic soft-tissue sarcoma after failure of at least two prior systemic therapy regimens.

    phase 2 small molecule active

    1 trial

  8. Fibromun, Darleukin

    Philogen S.p.A.

    Phase II, open label, multicentric, proof-of-principle basket trial in patients with malignant tumors of the skin amenable to intratumoral injection, and in a curative or neoadjuvant or palliative intention, including: • Basal cell carcinoma (BCC) • Cutaneous squamous cell carcinoma (cSCC) • Merkel cell carcinoma (MCC) • Keratoacanthoma (KA) • Malignant adnexal tumors of the skin (MATS) • Tumors from cutaneous T-cell lymphoma (CTCL) • Kaposi’s sarcoma (KS)

    phase 2 small molecule active

    1 trial

  9. Ficerafusp alfa

    Bicara Therapeutics

    Head and Neck Squamous Cell Carcinoma (HNSCC)

    phase 2 small molecule active

    1 trial

  10. Ficerafusp alfa

    Bicara Therapeutics

    Squamous Cell Carcinoma of Head and Neck (SCCHN)

    phase 2 small molecule active

    1 trial

  11. Filgotinib

    Lakefront Biotherapeutics NV

    Inflammatory Bowel Disease

    phase 2 small molecule terminated

    1 trial

  12. Filgotinib

    Lakefront Biotherapeutics NV

    Fistulizing Crohn's Disease

    phase 2 small molecule completed

    1 trial

  13. Filgotinib

    Lakefront Biotherapeutics NV

    Small Bowel Crohn's Disease

    phase 2 small molecule completed

    1 trial

  14. Filgotinib

    Lakefront Biotherapeutics NV

    Noninfectious Uveitis

    phase 2 small molecule terminated

    1 trial

  15. First-line Chemotherapy With Temozolomide Alone for Non-enhancing Adult Brainstem Gliomas, With a Diffuse Subtype and Showing Clinical and/or Radiological Infiltrative Pattern of Progression (TEMOTRAD01)

    Pari Pharma GmbH

    Adults with non-contrast-enhancing diffuse brainstem gliomas with non-threatening infiltrative clinical and/or radiological progression, Adult brain stem gliomas

    phase 2 other active

    1 trial

  16. First-line Cohort

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  17. Fisetin

    United Therapeutics Europe Ltd

    Femoroacetabular Impingement

    phase 2 small molecule active

    1 trial

  18. Fixed dose combination Ciprofloxacin/Celecoxib

    NeuroSense Therapeutics

    Amyotrophic Lateral Sclerosis

    phase 2 small molecule completed

    1 trial

  19. Fludarabina Accord 25 mg/ml concentrado para solución inyectable y para perfusión., HSP-CAR30, Levact 2,5 mg/ml poudre pour solution à diluer pour perfusion, RoActemra 20 mg/mL concentrate for solution for infusion, Genoxal 200 mg polvo para solución inyectable y para perfusión

    The George Institute

    Refractary or relapse non-Hodgkin T CD30+ lymphoma., Refractary or relapse Hodgkin T CD30+ lymphoma

    phase 2 small molecule active

    1 trial

  20. Fludarabine Teva 25 mg/ml solution à diluer pour injection ou perfusion, Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion, LN-145, Proleukin 18 x 106 IE Poeder voor oplossing voor injectie of infusie, Cyclophosphamide Injection 1 g., Fludarabine 50mg Powder For Solution For Injection Or Infusion, Endoxan, Флударабин Актавис 25 mg/ml концентрат за инжекционен или инфузионен разтвор, Fludarabinefosfaat – PCH 25 mg/ml, concentraat voor oplossing voor injectie/infusie, FLUDARAB

    Iovance Biotherapeutics B.V.

    Metastatic Non-Small-Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  21. Fluorouracil

    United Therapeutics Europe Ltd

    Clinical Stage II Esophageal Adenocarcinoma AJCC v8

    phase 2 small molecule active

    1 trial

  22. Fluorouracil

    United Therapeutics Europe Ltd

    Metastatic Biliary Tract Carcinoma

    phase 2 small molecule active

    1 trial

  23. Fluorouracil 50mg/ml Injection., FOLINIC ACID, Eftozanermin alfa, Telisotuzumab adizutecan, Oxaliplatin 5 mg/ml concentrate for solution for infusion

    AbbVie Deutschland GmbH & Co. KG

    Adenocarcinoma of the gastroesophageal junction

    phase 2 small molecule active

    1 trial

  24. Fluoxetine

    The First People's Hospital of Lianyungang

    Depression

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources